11 results on '"Lam B"'
Search Results
2. 763P Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance
3. 565P Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
4. 262MO Prognostic significance of deep and rapid prostate-specific antigen (PSA) response with docetaxel (DOC) or abiraterone (ABI): A territory-wide real-world analysis of 574 Asian metastatic hormone-sensitive prostate cancer (mHSPC) patients
5. 1349P Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases
6. Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers
7. 231TiP KEYNOTE-059: Phase 2 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma
8. P-105 Pembrolizumab (MK-3475) for patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: The phase 2 KEYNOTE-059 study
9. 386P - Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers
10. 689P Patterns of disease progression and efficacy of local ablative therapy among patients with metastatic EGFR-mutation positive non-small cell lung cancer treated with first-line osimertinib.
11. 320P Patient and clinician priorities and expectations of systemic therapy in metastatic urothelial cancer (mUC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.